Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma – final appraisal determination

In DRAFT guidance, NICE has recommended the use of brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone (CHP) as an option for untreated systemic anaplastic large cell lymphoma in adults, if it is provided according to the commercial arrangement.

National Institute for Health and Care Excellence